Agenus Inc. (NASDAQ: AGEN) stock fell -7.89% on Wednesday to $1.40 against a previous-day closing price of $1.52. With 3.75 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.5100 whereas the lowest price it dropped to was $1.3900. The 52-week range on AGEN shows that it touched its highest point at $3.31 and its lowest point at $1.23 during that stretch. It currently has a 1-year price target of $7.58. Beta for the stock currently stands at 1.43.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGEN was down-trending over the past week, with a drop of -4.76%, but this was down by -13.01% over a month. Three-month performance dropped to -31.74% while six-month performance fell -52.29%. The stock lost -9.13% in the past year, while it has lost -40.56% so far this year. A look at the trailing 12-month EPS for AGEN yields -0.81 with Next year EPS estimates of -0.73. For the next quarter, that number is -0.20. This implies an EPS growth rate of -641.50% for this year and -7.40% for next year.
Float and Shares Shorts:
At present, 317.11 million AGEN shares are outstanding with a float of 255.86 million shares on hand for trading. On Apr 27, 2023, short shares totaled 19.55 million, which was 5.72% higher than short shares on Mar 30, 2023. In addition to Dr. Garo H. Armen Ph.D. as the firm’s Founder, Exec. Chairman & CEO, Ms. Christine M. Klaskin serves as its VP of Fin., Principal Financial Officer & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 59.51% of AGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 7.25% of AGEN, in contrast to 38.81% held by mutual funds. Shares owned by individuals account for 22.90%. As the largest shareholder in AGEN with 9.02% of the stake, Deep Track Capital LP holds 30,000,000 shares worth 30,000,000. A second-largest stockholder of AGEN, SSgA Funds Management, Inc., holds 26,154,127 shares, controlling over 7.87% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in AGEN, holding 22,880,449 shares or 6.88% stake. With a 5.71% stake in AGEN, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 18,989,592 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.67% of AGEN stock, is the second-largest Mutual Fund holder. It holds 8,886,270 shares valued at 13.42 million. iShares Russell 2000 ETF holds 1.95% of the stake in AGEN, owning 6,489,573 shares worth 9.8 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, AGEN reported revenue of $20.93M and operating income of -$44.97M. The EBITDA in the recently reported quarter was -$34.22M and diluted EPS was -$0.17.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGEN analysts setting a high price target of $8.30 and a low target of $6.00, the average target price over the next 12 months is $7.58. Based on these targets, AGEN could surge 492.86% to reach the target high and rise by 328.57% to reach the target low. Reaching the average price target will result in a growth of 441.43% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded AGEN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
